Oncotelic Therapeutics Inc (QB) (OTLC)

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Oncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003

Publication Highlights Novel Intravenous Everolimus Formulation and Demonstrates Broad Potential of...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Oncotelic Launches AI-Powered GMP Manufacturing Services Platform at BIO International Convention 2026

Company to Showcase Integration of AI, Digital Batch Records, and Intelligent Robotics to Accelerate...

Form 4 - Statement of changes in beneficial ownership of securities

Oncotelic Advances AI-Powered GMP Manufacturing Services Platform for Revenue-Generating AI and Robotics Manufacturing Services

SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company...

Oncotelic Showcases PDAOAI™ Capability in Advancing Drug Development. Featured in Qdrant Vector Space Day 2026 Keynote

PDAOAI Platform Indexes 28 Million PubMed Abstracts on Qdrant; Introduces Manifold Folding to Solve the...

NetworkNewsAudio Announces Audio Press Release (APR) Discussing the Exploration of Nanoparticle, Targeted Drug-Delivery Technologies

AUSTIN, Texas, June 05, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release...

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Eyeing Nanotech-Driven Delivery Systems, Pharmacokinetic Optimization to Advance Existing Oncology Therapies

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today...

Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program

SAN DIEGO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Sapu Nano and Oncotelic Therapeutics (OTCQB:OTLC) today...

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Advancing Proprietary Solutions Focused on Nanotechnology-Enabled Drug Delivery, AI-Enhanced Biomedical Infrastructure

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today...

How Advanced Drug Delivery Could Improve Existing Cancer Treatments

AUSTIN, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: As oncology drug-development...